Literature DB >> 14751172

Correlation between responsiveness of neoadjuvant chemotherapy and apoptosis-associated proteins for cervical adenocarcinoma.

Tsuyoshi Saito1, Masaki Takehara, Ryoichi Tanaka, Rong Lee, Miyabi Horie, Koya Wataba, Eiki Ito, Ryuichi Kudo.   

Abstract

OBJECTIVE: Adenocarcinoma of the uterine cervix appears to be increasing in prevalence and it has been suggested that these tumors tend to be less sensitive to radiation therapy and to chemotherapy than squamous carcinomas. In the present study, 29 patients with locally advanced cervical adenocarcinoma (bulky IB-IVB) were treated with neoadjuvant chemotherapy (NAC) using cisplatin, aclacinomycin-A and mitomycin-C, followed by radical surgery or irradiation.
METHODS: To predict the prognosis and response to the chemotherapy, the expression of apoptosis associated-proteins, p53, p21WAF1/CIP1, Bcl-2 and activated caspase-3 was evaluated for tumor samples by immunohistochemistry.
RESULTS: Of the analyzed clinicopathological factors, the overexpression of p53 was frequently observed in endocervical-type adenocarcinoma, nonresponders to chemotherapy and the grade 0 histologic effect of the chemotherapy. Positive staining of Bcl-2 was frequently observed in the early stage and had a better prognosis than for patients with the negative staining; however, there was no correlation between responders and nonresponders to chemotherapy. The expression of p21WAF1/CIP1 and caspase-3 was not correlated to the clinicopathological factors.
CONCLUSION: In this study, the overexpression of p53 was found to be a factor to predict the chemoresistance and positive expression of Bcl-2 indicated as a better prognostic value. For p21WAF1/CIP1 and caspase-3, further analysis is necessary.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14751172     DOI: 10.1016/j.ygyno.2003.09.027

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN: 0090-8258            Impact factor:   5.482


  8 in total

1.  Factors affecting platinum sensitivity in cervical cancer.

Authors:  Rina Kato; Kiyoshi Hasegawa; Yutaka Torii; Yasuhiro Udagawa; Ichio Fukasawa
Journal:  Oncol Lett       Date:  2015-09-25       Impact factor: 2.967

2.  Comprehensive analysis of novel prognosis-related proteomic signature effectively improve risk stratification and precision treatment for patients with cervical cancer.

Authors:  Xiaoyu Ji; Guangdi Chu; Yulong Chen; Jinwen Jiao; Teng Lv; Qin Yao
Journal:  Arch Gynecol Obstet       Date:  2022-06-17       Impact factor: 2.344

3.  Clusterin expression inversely correlates with chemosensitivity and predicts poor survival in patients with locally advanced cervical cancer treated with cisplatin-based neoadjuvant chemotherapy and radical hysterectomy.

Authors:  Hidemichi Watari; Tatsuya Kanuma; Yoko Ohta; Mohamed Kamel Hassan; Takashi Mitamura; Masayoshi Hosaka; Takashi Minegishi; Noriaki Sakuragi
Journal:  Pathol Oncol Res       Date:  2010-01-08       Impact factor: 3.201

4.  Low-dose SN-38 with paclitaxel induces lethality in human uterine cervical adenocarcinoma cells by increasing caspase activity.

Authors:  Mizue Teramoto; Takahiro Suzuki; Seiro Satohisa; Yushi Akashi; Motoki Matsuura; Miwa Suzuki; Ryoichi Tanaka; Tsuyoshi Saito
Journal:  Med Mol Morphol       Date:  2013-03-16       Impact factor: 2.309

Review 5.  Molecular mechanisms of cisplatin resistance in cervical cancer.

Authors:  Haiyan Zhu; Hui Luo; Wenwen Zhang; Zhaojun Shen; Xiaoli Hu; Xueqiong Zhu
Journal:  Drug Des Devel Ther       Date:  2016-06-07       Impact factor: 4.162

6.  HP1γ Sensitizes Cervical Cancer Cells to Cisplatin through the Suppression of UBE2L3.

Authors:  Sang Ah Yi; Go Woon Kim; Jung Yoo; Jeung-Whan Han; So Hee Kwon
Journal:  Int J Mol Sci       Date:  2020-08-19       Impact factor: 5.923

Review 7.  Biological and clinical aspects of HPV-related cancers.

Authors:  Klaudia Anna Szymonowicz; Junjie Chen
Journal:  Cancer Biol Med       Date:  2020-12-15       Impact factor: 4.248

8.  CD34 and Bcl-2 as predictors for the efficacy of neoadjuvant chemotherapy in cervical cancer.

Authors:  Yun Lin; Zhi Li; Mubiao Liu; Haiyan Ye; Jianhui He; Jianguo Chen
Journal:  Arch Gynecol Obstet       Date:  2021-01-03       Impact factor: 2.344

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.